Vir Biotechnology Operating Expenses Growth & History (VIR)
Vir Biotechnology's operating expenses was $547.9M for fiscal 2025.
View full Vir Biotechnology company overviewVir Biotechnology annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $547.9M | −$113.5M | −17.16% |
| 2024 | 2024-12-31 | $661.4M | −$109.1M | −14.16% |
| 2023 | 2023-12-31 | $770.5M | −$12.2M | −1.56% |
| 2022 | 2022-12-31 | $782.7M | $108.1M | +16.02% |
| 2021 | 2021-12-31 | $674.7M | $301.3M | +80.71% |
| 2020 | 2020-12-31 | $373.3M | $187.3M | +100.65% |
| 2019 | 2019-12-31 | $186.1M | $56.7M | +43.84% |
| 2018 | 2018-12-31 | $129.4M | $45.2M | +53.63% |
| 2017 | 2017-12-31 | $84.2M | — | — |
Vir Biotechnology quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $165.5M | $45.8M | +38.32% |
| Q1 2026 | 2026-03-31 | $132.3M | −$10.3M | −7.24% |
| Q4 2025 | 2025-12-31 | $112.0M | −$17.5M | −13.54% |
| Q3 2025 | 2025-09-30 | $173.7M | −$60.0M | −25.68% |
| Q2 2025 | 2025-06-30 | $119.6M | −$42.1M | −26.02% |
| Q1 2025 | 2025-03-31 | $142.6M | $6.1M | +4.49% |
| Q4 2024 | 2024-12-31 | $129.5M | −$26.3M | −16.87% |
| Q3 2024 | 2024-09-30 | $233.7M | $44.3M | +23.40% |
| Q2 2024 | 2024-06-30 | $161.7M | −$57.3M | −26.16% |
| Q1 2024 | 2024-03-31 | $136.5M | −$69.9M | −33.86% |
| Q4 2023 | 2023-12-31 | $155.8M | −$44.1M | −22.06% |
| Q3 2023 | 2023-09-30 | $189.4M | $9.8M | +5.44% |
| Q2 2023 | 2023-06-30 | $219.0M | $34.4M | +18.63% |
| Q1 2023 | 2023-03-31 | $206.3M | −$12.3M | −5.63% |
| Q4 2022 | 2022-12-31 | $199.9M | −$41.1M | −17.05% |
| Q3 2022 | 2022-09-30 | $179.6M | $22.6M | +14.39% |
| Q2 2022 | 2022-06-30 | $184.6M | $68.5M | +59.06% |
| Q1 2022 | 2022-03-31 | $218.6M | $58.0M | +36.13% |
| Q4 2021 | 2021-12-31 | $241.0M | $130.9M | +118.82% |
| Q3 2021 | 2021-09-30 | $157.0M | $67.5M | +75.34% |
| Q2 2021 | 2021-06-30 | $116.1M | $20.0M | +20.84% |
| Q1 2021 | 2021-03-31 | $160.6M | $83.0M | +106.90% |
| Q4 2020 | 2020-12-31 | $110.1M | $45.4M | +70.13% |
| Q3 2020 | 2020-09-30 | $89.5M | $40.5M | +82.43% |
| Q2 2020 | 2020-06-30 | $96.0M | $58.2M | +153.96% |
| Q1 2020 | 2020-03-31 | $77.6M | $43.2M | +125.46% |
| Q4 2019 | 2019-12-31 | $64.7M | $34.8M | +116.36% |
| Q3 2019 | 2019-09-30 | $49.1M | $11.9M | +31.83% |
| Q2 2019 | 2019-06-30 | $37.8M | $10.6M | +38.94% |
| Q1 2019 | 2019-03-31 | $34.4M | −$558,000 | −1.59% |
| Q4 2018 | 2018-12-31 | $29.9M | — | — |
| Q3 2018 | 2018-09-30 | $37.2M | — | — |
| Q2 2018 | 2018-06-30 | $27.2M | — | — |
| Q1 2018 | 2018-03-31 | $35.0M | — | — |
Vir Biotechnology operating expenses trends
Over the last five fiscal years, Vir Biotechnology's operating expenses increased from $373.3M to $547.9M, a change of $174.5M. The latest reported quarter, Q2 2026, shows $165.5M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vir Biotechnology source filings ↗